000K utf8 1100 $c2021 1500 eng 2050 urn:nbn:de:gbv:8:3-2021-00875-0 2051 10.3389/fimmu.2021.765906 3000 Kouakanou, Léonce 3010 Brown, Christine E. 3010 Kabelitz, Dieter 3010 Peters, Christian 3010 Wang, Leo D. 4000 Vitamin C, From Supplement to Treatment$dA Re-Emerging Adjunct for Cancer Immunotherapy? [Kouakanou, Léonce] 4209 Vitamin C (VitC), in addition to its role as a general antioxidant, has long been considered to possess direct anti-cancer activity at high doses. VitC acts through oxidant and epigenetic mechanisms, which at high doses can exert direct killing of tumor cells in vitro and delay tumor growth in vivo. Recently, it has also been shown that pharmacologic-dose VitC can contribute to control of tumors by modulating the immune system, and studies have been done interrogating the role of physiologic-dose VitC on novel adoptive cellular therapies (ACTs). In this review, we discuss the effects of VitC on anti-tumor immune cells, as well as the mechanisms underlying those effects. We address important unanswered questions concerning both VitC and ACTs, and outline challenges and opportunities facing the use of VitC in the clinical setting as an adjunct to immune-based anti-cancer therapies. 4950 https://doi.org/10.3389/fimmu.2021.765906$xR$3Volltext$534 4950 https://nbn-resolving.org/urn:nbn:de:gbv:8:3-2021-00875-0$xR$3Volltext$534 4961 https://macau.uni-kiel.de/receive/macau_mods_00002287 5051 610 5550 Cancer Biology 5550 Cancer Immunotherapies 5550 Car (Chimeric Antigen Receptor) T Cells 5550 Immune Checkpoint Therapy (Ict) 5550 Vitamin C (Ascorbic Acid)